| Detailed information |
|---|
| CancerLivER ID | 2258 |
| Biomarker | Liver type aldolase |
| Biomarker Name/Symbol (given in Publication) | Liver type aldolase |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | Potential diagnostic marker; but not valifdated on independent dataset |
| Experimental Condition | HCC v/s non-tumor |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Downregulated in HCC than non-tumor |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 15221772 |
| Type of Biomarker | Diagnostic |
| Pathway | Glycolysis |
| Cohort | Paired tumor and non-tumor tissue samples form 20 HCC patients [Four patient's HCCs were well differen-tiated, 15 were moderately differentiated, and the last onewas poorly differentiated. Twelve out of the 20 nontumor-ous tissues indicated cirrhotic liver] |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | HCV-associated HCC |
| Year of Publication | 2004 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |